Hansoh Pharmaceutical Group Company Limited (3692.HK) stock analysis

In our weekly check, Hansoh Pharmaceutical Group Company Limited is graded B (A to F). Of 25 checks on debt, profit, cash flow and trend: 20 pass, warnings: 3, red flags: 2.

About Hansoh Pharmaceutical Group Company Limited

Hansoh Pharmaceutical Group Company Limited is a Healthcare company (Drug Manufacturers - Specialty & Generic) based in China, listed on HKSE as 3692.HK.

What our checks show for 3692.HK

Red flags

• The dividend takes 241% of profit: little cushion if profit falls.
• The stock has fallen as much as 79% from a peak. Would you have held through that?

Warning signs

• The gross margin fell by 1.3 points, to 89.9%: costs are rising faster than prices.
• The price swings a lot: 41.4% annual volatility. Expect large ups and downs.
• The stock is still below its previous peak.

Strengths

• Debt is low: 0.11x equity.
• Operating profit covers interest 257 times over.
• The net margin rose by 9.7 points over 5 years, to 37%.
• Operating cash flow is 1.21x net profit: the profit arrives as real cash.
• Analysts expect earnings per share to grow about 12% a year over the next years.
• Revenue grew 17% a year over the last 3 years.

Similar companies

6446.TW · TAK · MRK.DE · TEVA · LUPIN.NS · HLN

Questions

What grade does Hansoh Pharmaceutical Group Company Limited (3692.HK) have?

In our weekly check, Hansoh Pharmaceutical Group Company Limited is graded B (A to F). Of 25 checks on debt, profit, cash flow and trend: 20 pass, warnings: 3, red flags: 2. The grade is a risk check, not a buy or sell recommendation.

What are the main risks of 3692.HK stock?

This week's biggest flags for Hansoh Pharmaceutical Group Company Limited: Dividend stretched, Deep past fall, Gross margin falling. In total 5 of 25 checks show a warning or a red flag.

What does Hansoh Pharmaceutical Group Company Limited do?

Hansoh Pharmaceutical Group Company Limited is a Healthcare company (Drug Manufacturers - Specialty & Generic) based in China, listed on HKSE as 3692.HK.

The grade is a risk check, not a price forecast, and not investment advice. In our 10-year test (S&P 500, 2016-2026), stocks we graded A or B fell more than 30% 2-3 times less often than D or F, without a lower average return.

Updated 2026-10-24

Open the full analysis